Biomarkers in diabetic nephropathy: Present and future

查看全文 作　　者：Gemma [1]Currie;Gerard Mc [2,3]Kay;Christian [1]Delles

机构地区：[1]Institute of Cardiovascular and Medical Sciences,University of Glasgow;[2]School of Medicine,University of Glasgow;[3]Glasgow Royal Infirmary

出　　处：《World Journal of Diabetes》索引2014年第5卷第6期,共14页

摘　　要：Diabetic nephropathy(DN) is the leading cause of end stage renal disease in the Western world. Microalbuminuria(MA) is the earliest and most commonly used clinical index of DN and is independently associated with cardiovascular risk in diabetic patients. Although MA remains an essential tool for risk stratification and monitoring disease progression in DN, a number of factors have called into question its predictive power. Originally thought to be predictive of future overt DN in 80% of patients, we now know that only around 30% of microalbuminuric patients progress to overt nephropathy after 10 years of follow up. In addition, advanced structural alterations in the glomerular basement membrane may already have occurred by the time MA is clinically detectable.Evidence in recent years suggests that a significant proportion of patients with MA can revert to normoalbuminuria and the concept of nonalbuminuric DN is well-documented, reflecting the fact that patients with diabetes can demonstrate a reduction in glomerular filtration rate without progressing from normo-to MA. There is an unmet clinical need to identify biomarkers with potential for earlier diagnosis and risk stratification in DN and recent developments inthis field will be the focus of this review article. 关键词：glomerular EXCRETION CREATININE STRATIFICATION URINARY alterations FILTRATION predictive BASEMENT collagen

相关文献

参考文献（10）
引证文献（27）
耦合文献（0）

参考文献(10)

引证文献(27)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Biomarkers in diabetic nephropathy: Present and future

参考文献(10)

引证文献(27)

用户提示